-
BREAKING NEWS: Ocrevus still has life for PPMS patients in the NHS
The MS Trust reports that “NICE has announced that it is pausing the publication of final guidance for ocrelizumab for primary progressive multiple sclerosis.
The final decision was due to be published on the NICE website on 31 October and would have rejected ocrelizumab as an NHS treatment for primary progressive MS on the grounds of cost effectiveness.”
I think that’s great. What do you think?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.